» Articles » PMID: 37770420

Noninvasive Diagnosis of Pulmonary Nodules Using a Circulating TsRNA-based Nomogram

Overview
Journal Cancer Sci
Specialty Oncology
Date 2023 Sep 28
PMID 37770420
Authors
Affiliations
Soon will be listed here.
Abstract

Evaluating the accuracy of pulmonary nodule diagnosis avoids repeated low-dose computed tomography (LDCT)/CT scans or invasive examination, yet remains a main clinical challenge. Screening for new diagnostic tools is urgent. Herein, we established a nomogram based on the diagnostic signature of five circulating tsRNAs and CT information to predict malignant pulmonary nodules. In total, 249 blood samples of patients with pulmonary nodules were selected from three different lung cancer centers. Five tsRNAs were identified in the discovery and training cohorts and the diagnostic signature was established by the randomForest algorithm (tRF-Ser-TGA-003, tRF-Val-CAC-005, tRF-Ala-AGC-060, tRF-Val-CAC-024, and tiRNA-Gln-TTG-001). A nomogram was developed by combining tsRNA signature and CT information. The high level of accuracy was identified in an internal validation cohort (n = 83, area under the receiver operating characteristic curve [AUC] = 0.930, sensitivity 100.0%, specificity 73.8%) and external validation cohort (n = 66, AUC = 0.943, sensitivity 100.0%, specificity 86.8%). Furthermore, the diagnostic ability of our model discriminating invasive malignant ones from noninvasive lesions was assessed. A robust performance was achieved in the diagnosis of invasive malignant lesions in both training and validation cohorts (discovery cohort: AUC = 0.850, sensitivity 86.0%, specificity 81.4%; internal validation cohort: AUC = 0.784, sensitivity 78.8%, specificity 78.1%; and external validation cohort: AUC = 0.837, sensitivity 85.7%, specificity 84.0%). This novel circulating tsRNA-based diagnostic model has potential significance in predicting malignant pulmonary nodules. Application of the model could improve the accuracy of pulmonary nodule diagnosis and optimize surgical plans.

Citing Articles

Cell-free epigenomes enhanced fragmentomics-based model for early detection of lung cancer.

Wang Y, Guo Q, Huang Z, Song L, Zhao F, Gu T Clin Transl Med. 2025; 15(2):e70225.

PMID: 39909829 PMC: 11798665. DOI: 10.1002/ctm2.70225.


Diagnostic and prognostic values of tsRNAs in lung cancer: a meta-analysis.

Tang C, Sun S, Gu C, Li C, Xu J, Su K BMC Cancer. 2025; 25(1):153.

PMID: 39871144 PMC: 11770914. DOI: 10.1186/s12885-025-13536-y.


Research progress on the tsRNA biogenesis, function, and application in lung cancer.

Chen Y, Shao Z, Wu S Noncoding RNA Res. 2024; 10:63-69.

PMID: 39309197 PMC: 11414277. DOI: 10.1016/j.ncrna.2024.09.004.


Noninvasive diagnosis of pulmonary nodules using a circulating tsRNA-based nomogram.

Wang Q, Song X, Zhao F, Chen Q, Xia W, Dong G Cancer Sci. 2023; 114(12):4607-4621.

PMID: 37770420 PMC: 10728016. DOI: 10.1111/cas.15971.

References
1.
Mazzone P, Silvestri G, Souter L, Caverly T, Kanne J, Katki H . Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. Chest. 2021; 160(5):e427-e494. PMC: 8727886. DOI: 10.1016/j.chest.2021.06.063. View

2.
Kumar P, Mudunuri S, Anaya J, Dutta A . tRFdb: a database for transfer RNA fragments. Nucleic Acids Res. 2014; 43(Database issue):D141-5. PMC: 4383946. DOI: 10.1093/nar/gku1138. View

3.
Wu F, Chang Y . Toward More Effective Lung Cancer Risk Stratification to Empower Screening Programs for the Asian Nonsmoking Population. J Am Coll Radiol. 2023; 20(2):156-161. DOI: 10.1016/j.jacr.2022.10.010. View

4.
Swensen S, Silverstein M, Ilstrup D, Schleck C, Edell E . The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med. 1997; 157(8):849-55. View

5.
Keam S, Hutvagner G . tRNA-Derived Fragments (tRFs): Emerging New Roles for an Ancient RNA in the Regulation of Gene Expression. Life (Basel). 2015; 5(4):1638-51. PMC: 4695841. DOI: 10.3390/life5041638. View